Table 2.B. infantis 35624-feeding induces a reduction in absolute IL-6 and TNF-α levels in inflammatory disorder patients compared with placebo-fed patients. Results expressed as median (interquartile ranges).
| Disease Indication | Treatment | Cytokine | Pre-treatment level (pg/ml) |
Post-treatment level (pg/ml) |
|
|---|---|---|---|---|---|
|
Psoriasis |
B. infantis |
IL-6 |
1.62 (1.05–2.96) |
1.48 (0.94–1.93) |
|
| Placebo |
IL-6 |
1.73 (1.32–2.78) |
1.42 (1.12–2.47) |
||
|
Chronic Fatigue Syndrome |
B. infantis |
IL-6 |
0.73(0.60–0.96) |
0.66(0.50–0.85 |
|
| Placebo |
IL-6 |
0.85 (0.70–1.21) |
0.92 (0.83–1.27) |
||
|
Ulcerative Colitis |
B. infantis |
IL-6 |
2.17 (1.05–3.96) |
1.98 (1.29–2.60) |
|
| Placebo |
IL-6 |
3.28 (1.05–4.95) |
5.57(1.39–7.96) |
||
|
Psoriasis |
B. infantis |
TNF-α |
8.20 (7.12–11.05) |
7.67 (6.57–8.43) |
|
| Placebo |
TNF-α |
7.06 (6.48–8.10) |
7.40 (6.35–8.91) |
||
|
Chronic Fatigue Syndrome |
B. infantis |
TNF-α |
7.50 (6.42–7.85) |
6.82 (5.75–9.22) |
|
| Placebo |
TNF-α |
8.01 (6.07–8.90) |
8.36 (6.88–9.84) |
||
|
Ulcerative Colitis |
B. infantis |
TNF-α |
9.38 (7.49–9.84) |
7.12 (8.77–9.84) |
|
| Placebo |
TNF-α |
6.82 (5.75–9.22) |
7.03 (5.48–9.18) |
||